Information Provided By:
Fly News Breaks for November 8, 2016
RMTI
Nov 8, 2016 | 06:40 EDT
As previously reported, BofA/Merrill downgraded Rockwell Medical to Underperform from Neutral and lowered its price target to $5 from $9. Analyst Tazeen Ahmad said Q3 results proved little visibility into when Triferic may launch, and as a result, removed his 2016 sales forecasts and ramp rate. Ahmad now assumes peak Triferic sales of $104M in 2024, versus $153M previously and notes Calcitriol manufacturing issues have resulted in a delayed launch of that product.
News For RMTI From the Last 2 Days
There are no results for your query RMTI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.